Search
for

    Sort by

    Research 481–510 of 1000+

    1. Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1‐day and a 3‐day regimen Mycoses · 2005 · 12 citations
    2. Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis Nature Communications · 2023 · 11 citations
    3. Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche. Journal of Investigative Dermatology · 1998 · 10 citations
    4. [Cushing syndrome during pregnancy. New diagnostic methods used in 3 cases of adrenal cortex carcinoma]. PubMed · 1992 · 10 citations
    5. Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968) Journal of Medicinal Chemistry · 2015 · 6 citations
    6. Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase Bioorganic & Medicinal Chemistry · 1997 · 5 citations
    7. Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2023 · 4 citations
    8. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment American Journal of Clinical Dermatology · 2025 · 3 citations
    9. 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies Journal of Investigative Dermatology · 2023 · 3 citations
    10. Long‐Term Follow‐Up of Previously Reported Case of Trichomegaly Associated with Alopecia Areata in a 3‐Year‐Old Girl Pediatric Dermatology · 2012 · 3 citations
    11. Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3 Dermatology · 2024 · 2 citations
    12. 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study British Journal of Dermatology · 2024 · 1 citations
    13. 76957 Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program Journal of the American Academy of Dermatology · 2026
    14. 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program Journal of the American Academy of Dermatology · 2026
    15. Assessment of The Long-Term Negative Impact of Bariatric Surgery on Health in Saudi Adults, over 3 Years after Surgery: A Cross-Sectional Study Saudi Journal of Medicine and Public Health · 2025
    16. Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2025
    17. Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials SKIN The Journal of Cutaneous Medicine · 2024
    18. Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata SKIN The Journal of Cutaneous Medicine · 2024
    19. Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years 2024
    20. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata Journal of The American Academy of Dermatology · 2023
    21. Referee report. For: Effect of Aloe vera extract in post-burn skin repair in rats [version 3; peer review: 2 approved, 1 not approved] Faculty of 1000 Research Ltd · 2023
    22. Peer Review Report For: Pattern changes of cutaneous dermatoses among Iraqi women preceding and during the COVID-19 pandemic [version 3; peer review: 2 approved] 2022
    23. Supplementary Images & Discussion - Tolerated, Effective, Successful: Low Dose Oral Minoxidil for Treating Alopecia, A 3-Year North American Retrospective Case Series 2020
    24. Tratamento de alopecia androgenética (AAG) masculina com extrato de chá verde (Camellia Sinensis) com ênfase no ativo epigalocatequina galato 3 2019
    25. Synthesis, Biological Evaluation and in silico Studies of Novel 5α-aza-Bhomo-3,5-secosteroids as Potential 5-reductase Inhibitors Letters in Drug Design & Discovery · 2016
    26. Posters Presented at the 19th Joint Meeting of the International Society of Dermatopathology, March 2–3, 2016, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia, USA American Journal of Dermatopathology · 2016
    27. インタビュー 内井乃生夫人に聞く 宮崎台ビレジに見る建築家内井昭蔵の姿勢 (39年の時を経た名建築に住む 宮崎台ビレジ--設計=内井昭蔵建築設計事務所) 住宅建築 · 2010
    28. 任意方向の負荷に対する多自由度機構の出力変位誤差評価 : 評価法の提案と3自由度空間パラレルメカニズムの高剛性化(機械力学,計測,自動制御) 日本機械学會論文集. C編 · 2005
    29. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial The Lancet · 2023 · 227 citations
    30. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat 3 3Abbreviations: r5AR1, rat 5α-reductase 1; r5AR2, rat 5α-reductase 2; and DHT, dihydrotestosterone. Biochemical Pharmacology · 2001 · 22 citations